Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah Man! ...and why not!? Seems like with the last few trading sessions, it's time for removal of the "IPIX penalty." There are too many converging positive factors right now, both technical and fundamental.
Both Mr. Ehrlich and Mr. Loan have verbiage requirements peculiar to each.
About 15 months ago, OTC competitor CYDY had over a 2 Billion market cap and close to a $10 share price as I recall. Several of the other baby bios in this same space had over a 1 Billion MC in their heyday.
Infer what you will for IPIX going forward, if news is good.
The legend of that particular price revolved around biomanbaba and the promise of Kevetrin. Way before Polymedix and Brilacidin were captured by Leo and Krishna.
Biomanbaba is no longer on the planet, but he's no doubt smiling ... RIP
Surely you can offer an opinion in response to your own question?
I just want to know which ER in which hospital to stay away from.
Thanks
my auto spell corrected to: the bears will soon be beached and the regiment will disband.
lol
Excellent and informative post! Stage is set.
The first is already happening and the second has always been true. Sometimes historical reminders are needed, like the many fake "walls" from .07 on up, and the many lies spoken about Mr. Ehrlich that continue to this day.
Yep, and it could come quickly. I can hardly wait for # 10 on this list to materialize as very positive PH II results:
So far many signs are converging:
1. FDA fast track designation- January
2. Validation by 2 independent machine learning studies- March
https://www.ipharminc.com/press-release/2021/3/10/innovation-pharmas-covid-19-drug-candidate-brilacidin-ranked-in-top-three-percent-of-compounds-predicted-to-be-most-effective-against-sars-cov-2
3. Peer-Reviewed scientific article published in journal Viruses- March-- https://www.mdpi.com/1999-4915/13/2/271
4. 2 separate Data Monitoring Committee safety reviews are completed on PH II patients- April and after.
5. Subsequent FDA approved Compassionate use begins in hospitalized patients using Brilacidin.
6. PH II results anticipated week of Nov. 8th
7. Management 8ks new milestone-based incentive package for CEO and Board on Oct. 14
8. Dr. Degrado, IPIX scientific advisor and developer of Brilacidin publishes new paper and gives prestigious lecture on de novo design of membrane-interactive peptides. Oct. 21st
9. IPIX share price continues to rise last few sessions
10.
If you can't beat 'em... join 'em??
Leo's been wrongly accused of spending too much time at the beach, but I had no idea he was also inventing and testing medicines there... If so, Nobel Prize for sure!
Many signs converging:
1. FDA fast track designation- January
2. Validation by 2 independent machine learning studies- March
https://www.ipharminc.com/press-release/2021/3/10/innovation-pharmas-covid-19-drug-candidate-brilacidin-ranked-in-top-three-percent-of-compounds-predicted-to-be-most-effective-against-sars-cov-2
3. Peer-Reviewed scientific article published in journal Viruses- March-- https://www.mdpi.com/1999-4915/13/2/271
4. 2 separate Data Monitoring Committee safety reviews are completed on PH II patients- April and after.
5. Subsequent FDA approved Compassionate use begins in hospitalized patients using Brilacidin.
6. PH II results anticipated week of Nov. 8th
7. Management 8ks new milestone-based incentive package for CEO and Board on Oct. 14
8. Dr. Degrado, IPIX scientific advisor and developer of Brilacidin publishes new paper and gives prestigious lecture on de novo design of membrane-interactive peptides. Oct. 21st
9. IPIX share price rises last few sessions
This is a post every new person should read. It explains this recent article in everyday language.
New Dr. Degrado article published October 21, 2021: Spiers Memorial Lecture: Analysis and de novo design of membrane-interactive peptides
https://pubs.rsc.org/en/content/articlelanding/2021/FD/D1FD00061F
Have a good weekend with reality, brought to you by IPIX
and for every IPIX there are a million duds
Interesting post... a fellow long's opinion from elsewhere:
"What are the XXX going to do when big news of B-CV19 trial success, Compassionate Use (CU) and funding (government grants and/or BP partnership) is announced and a flood of new retail and momentum investor dollars flood the market? What are the XXX going to do when IPIX Up Lists and is over $5 share at which point institutional money (sector funds, index funds, mutual funds) significantly drives further demand for IPIX shares?
"The interesting piece of Monday’s PR is that the more testing that is done, the more Brilacidin looks like it could be the next penicillin discovery as a treatment for a large variety of viruses and disease as a new class of drug.
"I think the RBL initial testing started in May 2020 and the PR on 6/11/20 discussed a heavily discounted $35k for the RBL to do advanced testing. I believe testing has been ON-GOING since that point as the RBLs continue to apply for small grant funds to explore how Brilacidin treats various types of viruses and disease. Initially this testing was a pre-cursor to establish the B-CV19 Phase 2 specific protocols. Once the trial was in place additional enveloped viruses were tested at which point IMO the DoD became interested in B as a biodefense weapon. Recent news includes success testing B to treat non-enveloped viruses. The list of viruses and diseases that Brilacidin could treat keeps getting larger per Monday’s PR. I am also guessing that after the trial commenced that the RBLs continued to push the envelope on safety testing to see the limits of maximum dose levels and frequency of treatments. We will know more once dosing levels have been announced with Top Line Results (TLR) and possibly with Compassionate Use (CU) success announcements.
"IMO TLR and CU results will be positive and PRed in November. Funding (via government grants or BP deals) by EOY. The continued B testing should spark some BP interest above and beyond treating CV19 and could be an incentive for a BP to do a B franchise deal. I think the FDA will be forced to approve EUA for Critical CV19 patients based on CU success. This is the opening for B to be advanced through the FDA bureaucracy and get full NDA approval late 2022/early 2023. EUA revenue and BP licensing should be enough for Leo to Up List in Q1 2022 which will force a large amount of covering.
"There are a lot of dominos in place but solid TLR and CU results will start the domino chain followed by funding, EUA, NSS initial covering, Up Listing, multiple POC and mini trials throughout 2022 and separately initiation of the B-IBD UC trial. Brilacidin may not be a fully approved NDA drug until 2023 but hundreds of millions in revenue dollars will flow in 2022 via EUA."
"All IMO."
The 15:59:59 paint downs are getting old, and are very transparent.
Tomorrow should be interesting. AI news in the middle east travels fast.
Not much time left before results come.
Huge block buying... looks like the atmospheric sentiment algos have changed as well.
Annual reviews usually mean some will need to sharpen up their resumes.
Now where have I put my sunglasses?
Bad boy MMs Nite and Cdel making a last stand to prevent .30?
Boy are they going to be surprised if results are as good as some think.
Leo's not interested in brown furry creatures
Khan came on in March, the acquisition of SmartAxiom closed a month or two after that. Either they realized that amateur pumps weren't going to help the SP, or Woloshin and Abrams told them to STFU.
Since early August the amateur pumping by the company has pretty much stopped.
Khan said it would take about a year and Woloshin and Abrams have not bailed as far as I know. Company has been cleaning-up debt, albeit with some dilution.
If they've got worthwhile technology and bigger fish are interested in their product, we'll know within the next 6 months.
No "ifs" needed for FDA fast track, apparent military interest, AI research validation, in vitro validation, and several PH II clinical trials
One of the strategies MMs sometimes use to demoralize traders, IMO, is to jack the price up early in the day, and then bring it down slowly as volume subsides to try to end the day with a slight loss. This leads to the pessimistic outcry that "this stock never goes up."
Lately, this pattern has reversed, which bodes well for the algos changing... and perhaps changing in a big way as we get closer to results.
Waiting for next news to hit.
Break of .30 is an important level
Thanks for the copy and paste of criteria for "Penny Stock Exempt" status. Good to see IPIX qualifies.
"To qualify as “Penny Stock Exempt” on the OTC Markets, an issuer must satisfy one of the following requirements: (i) the issuer’s securities have a minimum price greater than $5 per share; (ii) the issuer has average revenues of at least $6 million for the last three (3) years; or (iii) the issuer has net tangible assets exceeding $2 million, if the issuer has been in continuous operations for at least three (3) years or $5 million if less than three (3) years."
Huge volume will come when media outlets discover Brilacidin, and discovery of B will come with good results from the PH II trial.
Any day now news will come... Maybe Leo will surprise before the week of Nov. 8th?
Wouldn't that be sweet. In any case, just 7 more trading days until the week of Nov. 8th.
If it takes longer than that, then Leo's probably negotiating deals, IMO.
IPIX is designated currently as "penny stock exempt."
They have enough assets for this designation.
I suspect institutions will soon be on board and after $5 share price who know where it might go. All assuming results are good.
Doubt any real shareholders are selling this close to news, but the MMs DO like to exert control, especially end of day.
Wonder if we'll see another 15:59:59 paint job to take it down?
Interesting claims of buying today
Excellent post! I guess all the negative arguments now have little ground to stand on.
Waiting for results.
Algos are about to change, IMO, and one can already sense a slow but steady positive transition accompanying the slow rise of the share price.
MMs won't change in any big way until hit over the head with volume.
This could bust loose at any moment, IMO. Arguments against the CEO have failed, and arguments against Brilacidin will look silly if clinical trial results are anywhere near in vitro findings
Important to note how careful Leo has been to be quiet and follow the FDA guidelines. No penny rag "articles" bought and paid for with free shares.
He won't need to if results are as good many think they'll be. Every news outlet in the world will be touting IPIX and Brilacidin.
A link is so easy to find, isn't it?
https://www.healthindustrywashingtonwatch.com/2021/09/articles/department-of-health-and-human-services/biden-administration-looks-to-centralize-pandemic-response-in-preparedness-plan/
A majority of the funds will go to the effort to transform medical defenses, more specifically to the development of vaccines ($24.2 billion), therapeutics ($11.8 billion), and diagnostics ($5.0 billion).
As far as no phase 3s? That's an old argument that's been beat into the ground, and has no relevance for this baby bio, strapped for funds and careful to dilute minimally, while setting up for these potentially lucrative trial results for moderate to severe Covid in hospitalized patients. All of the previous phase 2s have shown safety and indications of efficacy.
Anyone thinking Leo has diluted too much should look at other OTC companies in the same medical areas and their number of outstanding shares.
Inconsistencies are perfectly consistent in an imperfect world. A little bit like dislocations in the price of IPIX stock.
But that's how money is made: dislocations in a stock's price.
Over 11 billion dollars waiting to help an anti-viral with good results, and Brilacidin has never failed a clinical trial.
Leo's chess move and hedge against powers that be in one place or the other:
That makes two days in a row an order went off at 15:59:59 to lower the share price. It happened both Monday and Tuesday so far. The MMs are nutty if they think they are able to demoralize or negatively influence those who know the research and potential of Brilacidin.
CEO bashing on the OTC is older than the oldest profession in the world.
Very true and it's why the word "anticipated" is used to estimate when topline results might come out. The CEO has no control over when the statistics vendor gets the unlocked data and runs the programs for comparison data.
Brilacidin has never failed a clinical trial, and while it's pins and needles time as we wait, I'm personally feeling confident given the drug's performance in other clinical trials and in vitro at the Regional Bio Labs.
Would love to see it all released next week though.
Over 11 Billion federal dollars in the US is standing by, ready to assist the next anti-viral that works well.
Throw in anti-inflammatory, immunomodulating as a bonus.